. THC, the main psychoactive component of cannabis 10 , elicits its acute psychoactive effects through the endocannabinoid type 1 receptor (CB 1 R) 11 . THC has been linked to the rewarding aspects of cannabis and the induction of symptoms of mental illnesses and cognitive impairment. Recently, the THC content of cannabis has been increasing 12 and synthetic THC analogues (potent cannabinoid receptor agonists; termed 'spice') are now widely used 13 . The likelihood of a future increase in consumption of cannabinoids through electronic cigarettes (cannavaping) and edible products 14 changes the landscape further 15 . Given the widespread use of cannabinoids, and the links between THC exposure and adverse outcomes, it is imperative that the neurobiological effects of THC are understood. Recently, we and others have found that heavy cannabis use is associated with reductions in dopaminergic function. Since both the rewarding and psychotogenic effects of THC and its analogues are thought to be mediated by the dopaminergic system, demonstrating dopaminergic alterations in human users in vivo is of clinical relevance for the prevention and treatment of cannabis-use-associated disorders and psychoses. Therefore, we present a review of the animal and human literature on the complex effects of acute and longer-term THC administration on dopamine synthesis and release and on its receptors, providing an account of the current understanding of the field. We critically analyse the factors that contribute to the effects of THC, and to variations between studies, before providing a framework for future research including a pharmacological dissection of these effects, especially in the developing brain.
THC receptor binding in the brain
THC is a CB 1 R and endocannabinoid type 2 receptor (CB 2 R) partial agonist 11 . The psychoactive effects of THC are blocked by the CB 1 R antagonist rimonabant 16, 17 , indicating that these effects are mediated through the activation of G-protein-coupled CB 1 R receptors, which reduce cAMP levels by inhibiting adenylate cyclase 18 . THC disrupts finely tuned endocannabinoid retrograde signalling systems owing to the temporal and neuronal specificity of endocannabinoids over THC. Under conditions of low CB 1 R density, THC antagonizes endogenous agonists that possess greater receptor affinity than THC 19 . THC also allosterically modulates opioid receptors 20 , which may provide additional indirect routes for altering dopamine transmission 21 . Furthermore, THC has psychoactive metabolites with CB 1 R affinity, further complicating the analysis of receptor-binding studies 22 .
CB 1 receptors and dopamine
Early animal studies described the interactions of amphetamine, which increases dopamine release, and THC 23 . These studies reported that the behavioural effects of amphetamine were potentiated or antagonized, depending on the dose of THC, leading researchers to propose that dopamine was "a prime candidate for…the mode of action of Δ 9 -tetrahydrocannabinol" 24 . Indeed, THC produces complex effects on the dopamine system, contributing to the drug's recreational and harmful effects. However, there are inconsistencies between the preclinical and clinical findings, which have proven challenging for researchers in the field. It is, therefore, timely to review the evidence and provide a framework for understanding the inconsistencies between the preclinical and clinical findings. Dopaminergic neurons are modulated by the endocannabinoid system 25 . CB 1 Rs and the endocannabinoid ligands anandamide and 2-arachidonoylglycerol (2-AG) are abundant in dopaminergic pathways, including in the striatum 26 , where they act as a retrograde feedback system on presynaptic glutamatergic and γ-aminobutyric acid (GABA) nerve terminals ( Fig. 1) , modulating dopamine transmission. Anandamide 27 and 2-AG 28 stimulate dopamine release in the nucleus accumbens (NAc) shell. Again, this effect is blocked by the CB 1 antagonist rimonabant, indicating that the dopaminergic effects of endocannabinoids involve CB 1 receptors. The rewarding properties of THC, which are mediated through increased dopamine release and dopaminergic neuron firing, are underpinned by biased signal transduction mechanisms from
The effects of Δ 9 -tetrahydrocannabinol (THC), the main psychoactive ingredient in cannabis, are a pressing concern for global mental health. Patterns of cannabis use are changing drastically owing to legalization, the availability of synthetic analogues (commonly termed spice), cannavaping and an emphasis on the purported therapeutic effects of cannabis. Many of the reinforcing effects of THC are mediated by the dopamine system. Owing to the complexity of the cannabinoid-dopamine interactions that take place, there is conflicting evidence from human and animal studies concerning the effects of THC on the dopamine system. Acute THC administration causes increased dopamine release and neuron activity, whereas long-term use is associated with blunting of the dopamine system. Future research must examine the long-term and developmental dopaminergic effects of THC.
. There is evidence that acute and chronic THC exposure have differing effects on the dopaminergic system. We will, therefore, deal with these separately and describe their effects on different neurobiological components of the dopaminergic system, including neuron firing, synthesis, release, reuptake and receptors.
Acute THC and presynaptic dopamine in animals
It has long been clear that THC exerts complex effects on the dopamine system. Early in vitro studies in rodent cells, using radiolabelled dopamine in synaptosomes, found that treatment with THC caused increased dopamine synthesis 29 and release 24 ( Fig. 2 and Box 1). However, the effects on dopamine uptake yielded conflicting results, with evidence of both increases 30 and dose-dependent decreases 24 . Subsequently, biphasic and triphasic effects of THC were discovered, whereby low doses of THC produced increases in the conversion of tyrosine to dopamine, but high doses of THC resulted in decreased dopamine synthesis 31 . Similarly complicated temporal relationships between THC administration and changes in dopamine levels were observed 32 , with repeated dosing resulting in behavioural and neurochemical tolerance-highly pertinent to the mechanisms of dependence to the drug. The complex dosespecific effects of THC in rodents were thought to be due to dose-related decreases in precursor uptake 30 and dopamine-opioid interactions via μ-opioid receptors 29 . Subsequent work investigated THC-induced increases in dopamine synthesis in vivo. THC increased 3 H-dopamine synthesis 33, 34 , tyrosine hydroxylase protein levels 35 and mRNA expression 36 , the rate-limiting step in the dopamine synthesis pathway. Similarly, increases in dopamine metabolism, measured through the dihydroxphenylacetic acid/dopamine (DOPAC/DA) ratio, were reported in most 37 , but not all 35 , rodent studies. However, the majority of early studies using spectrophotofluorimetry were inconsistent due to technical limitations in detecting the rapid changes in extracellular dopamine concentration, deviations that are now detectable using contemporary microdialysis techniques 38 .
In vivo microdialysis shows that acute THC administration increases dopamine efflux in the prefrontal cortex (PFC) 39 , striatum 40 and NAc
41
. Only one study did not find that THC induced increases in dopamine efflux 42 , an anomaly that may have been related to the route of administration as that study used a THC gavage-the other studies used intravenous injection, which produces a rapid increase in THC which reaches the brain promptly, whereas gavage favours sequestration in lipid compartments owing to the very high lipid solubility of THC 43 . Electrophysiological studies in rats have categorically demonstrated that THC dose-dependently increases firing rates in ascending midbrain dopaminergic projections via CB 1 R agonism 45, 46 . Together, these findings suggest that THC increases the firing rates of dopamine neurons, leading to increased dopamine synthesis and release in terminal fields.
Acute THC and postsynaptic dopamine in animals
Acute THC administration did not alter dopamine receptor protein levels in rhesus monkeys 47 . In the rat limbic forebrain, one study reported 135 . Endocannabinoids influence synaptic signalling in the midbrain. 2-AG is synthesized by diacylglycerol lipase in dopaminergic midbrain neurons and, once released, acts retroactively on CB 1 Rs on nearby glutamatergic and GABAergic terminals. CB 1 Rs mediate robust inhibition of GABA inputs onto midbrain dopamine cells 136 , termed retrograde suppression of inhibition. CB 1 Rs are also localized on glutamatergic terminals that synapse onto midbrain dopamine neurons 137 , where endocannabinoids mediate retrograde suppression of excitation. Thus, endocannabinoids fine-tune the activity of the mesolimbic dopamine projections through the modulation of both excitatory and inhibitory signalling and THC disrupts this system. REVIEW RESEARCH increased dopamine type 1 receptor (D 1 R) availability 48 whereas other studies reported decreases 49 . In the striatum, the density of dopamine type 2 receptors (D 2 Rs) either decreased 49 or did not significantly change, with decreases in D 1 R also reported 48 . That there is no change in receptor protein levels, together with the tendency towards reduced receptor availability, almost certainly reflects THC-induced changes in synaptic dopamine levels.
Acute THC and dopamine in humans
Studies of brain activity in humans, using functional magnetic resonance imaging (fMRI) and positron emission tomography (PET), provide indirect measures of dopaminergic function through changes in cerebral blood flow and glucose metabolism. These serve as surrogate markers of brain activity in areas with dopaminergic projections. In humans, acute THC administration is associated with increased activity in frontal and sub-cortical regions 50 . However, as the CB 1 R has the highest concentrations in these regions 51 these findings may be due to direct effects on the endocannabinoid system rather than representing dopamine-mediated processes. When studies investigating the effects of acute THC administration on resting brain activity have focused on regions with dense dopaminergic innervation, such as the striatum, there have been inconsistent findings, with reports of both increased and reduced activity 50 . However, certain cognitive tasks are modulated by dopaminergic signalling and may provide a more robust proxy for THC-induced changes in dopaminergic transmission. For example, motor response inhibition is associated with cortical dopamine release; an fMRI study of healthy humans with previous exposure to cannabis found that THC attenuates activation in the right inferior frontal cortex and the anterior cingulate cortex (ACC) during suppression of motor inhibition 52 . Further indirect evidence of blunted dopaminergic processing comes from a study of healthy humans with previous exposure to cannabis using a verbal working memory task in which it was found that THC attenuated striatal activation 53 . Additionally, a study of reward function in occasional cannabis users found that THC induced widespread attenuation of the brain response to feedback in reward trials 54 but not under rewardanticipation conditions 54 . It is also possible to directly measure activity of the dopamine system using molecular imaging. These studies have examined the effect of acute THC administration on dopamine release in humans with previous exposure to cannabis in vivo. Using PET, a combined analysis 55 of two previous studies has shown that THC does indeed cause dopamine release in the ventral striatum in the human brain 55 . Likewise, acute THC challenge elicited dopamine release in fronto-temporal cortical brain regions 56 , although this finding requires replication with radiotracers that show higher affinity for cortical dopamine receptors. However, in a separate study using single-photon emission-computed tomography (SPECT), no significant THC-induced dopamine release was observed 57 , which may be due to the relatively small sample size (n = 9) and the lower sensitivity of SPECT than PET to dopamine measures. This is likely to be because THC-induced dopamine release in the striatum appears to be of a lower magnitude than that caused by other drugs such as amphetamine and methylphenidate 58 , combined with difficulties in imaging dopamine changes that are comparatively small 59 .
Repeated THC treatment and presynaptic dopamine
Studies of repeated THC dosing have yielded complex, region-specific effects, such as increased total striatal dopamine levels in rats 60 but reduced hippocampal dopamine levels in mice 61 . Reduced dopamine metabolism was found in the medial PFC in two rat studies 60 , an effect that was not observed in the striatum or the NAc 62 . Administration of THC for 21 days downregulated tyrosine hydroxylase mRNA expression in the substantia nigra and ventral tegmental area (VTA) midbrain nuclei, but not in the cortex or striatum 63 . Several studies have reported that multiple THC doses do not significantly change dopamine release in the NAc in rats 64 . However, this may be due to differing dopaminergic responses within the NAc; in one rat study, repeated THC doses led to increased dopamine release in the NAc core but decreased release in the NAc shell 65 . The picture is further complicated by genetic strain effects, with increased dopamine release in the NAc observed in Lewis, but not Fischer 344, rat strains 66 . Together, these studies indicate that repeated THC dosing produces region-specific effects on dopamine function.
Studies in human cannabis users
Several molecular imaging studies of dopaminergic function have been conducted in human cannabis users. Using PET, the capacity for dopamine synthesis was observed to be reduced in cannabis users 67 . Notably, this reduction was driven by users meeting clinical criteria for abuse or dependence and was related to the degree of cannabis use (Fig. 3) . Similarly, in two separate studies, cannabis users exhibited reduced dopamine release to a stimulant challenge, which was related to degree of cannabis use 68 , and cognitive deficits that included poor working memory 69 . Since no alteration in amphetamine-induced dopamine release was seen in recently abstinent cannabis users 70 , this effect is likely to be related to active use of the drug. Although chronic use was not associated with alterations in stress-induced dopamine release 71 , there was evidence of a positive relationship between the duration of cannabis use and the level of stress-induced dopamine release in the limbic striatum 71 . Likewise, recent data show that cannabis users have an attenuated metabolic response to methylphenidate challenge in the striatum, with a negative relationship between methylphenidateinduced metabolic increases and severity of cannabis use 72 . There is also evidence of reduced dopamine transporter (DAT) density in chronic cannabis users 73 . Although the interpretation of some of these studies is complicated by the fact that cannabis users also frequently smoke tobacco, a recent experiment has addressed this by studying cannabis users without comorbid substance dependence, showing that cannabis users do indeed exhibit reduced dopamine release 69 . Overall there is converging evidence that presynaptic dopaminergic function is reduced in cannabis users.
BOX 1
Glossary of methods used to assess dopaminergic activity after THC exposure 
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Repeated THC administration and postsynaptic dopamine
Studies in rats have reported that multiple THC dosing results in increased D 2 R availability in the midbrain, striatum and PFC 63, 74 and that this is associated with dopamine receptor sensitization. There is further evidence of downstream dopaminergic effects of THC; one study in rats 75 reported upregulated postsynaptic dopamine receptor signalling in the NAc through an increase in adenylyl cyclase activity, which was proposed to underlie THC-induced changes in amphetamine-induced locomotive behaviour. These findings suggest that repeated THC dosing results in altered dopamine receptor signal transduction.
Dose-dependent increases in burst-firing in the VTA in response to multiple THC administrations have been reported in nearly all murine electrophysiological studies 46 , with only one exception of which we are aware 76 . In the substantia nigra pars compacta (SNpc), multiple THC dosing was associated with increased neuronal firing, although this increase was smaller in magnitude than in the VTA 77, 78 . This suggests that VTA and SNpc dopamine neurons develop differing responses to repeated THC exposures. There also appears to be an effect of withdrawal from multiple THC doses, whereby decreased firing is elicited by the abrupt cessation of repeated THC or administration of the CB 1 R antagonist SR141716A (ref. 79) .
Recent studies in current cannabis users and abstinent former users have found no significant difference in striatal D 2 R availability compared to individuals with no history of chronic cannabis use [68] [69] [70] [80] [81] [82] . However, there was an inverse relationship between the age of first cannabis use and D 2 R availability in one study 70 and an inverse relationship between current cannabis use and receptor availability in another study 80 , suggestive of possible dose effects or susceptibility to drug use.
THC exposure and dopamine cell morphology
In addition to changes in cell function, there is evidence from studies in rodents that THC exposure causes abnormalities in the structure of dopamine neurons. These morphological effects are region-specific and include reductions across a range of measures of neuronal cell size in the VTA 83, 84 and increased neuronal arborization in the NAc shell and frontal cortex 85 .
Developmental THC exposure and dopamine
Adolescence is an important time for brain development and adolescent cannabinoid exposure has consequences in adulthood 86 . The endocannabinoid system plays an important role in brain development 87 ; developmental THC exposure produces complex alterations in the dopamine system that are apparent from an early stage. For example, gestational THC exposure is associated with increased fetal brain tyrosine hydroxylase mRNA expression in rats 88 and changes in dopamine receptor gene expression. THC exposure in early development is associated with increased cortical D 2 R availability 89 . In rats, exposure to THC from gestational day 5 to post-natal day 21 resulted in decreased levels of DRD2 mRNA (encoding D 2 R) in the NAc. Likewise, human maternal cannabis use was associated with decreased DRD2 mRNA in the fetal NAc 90 . Exposure to THC in early life also blunts the dopaminergic response to dopamine-releasing stimuli, such as stress and amphetamine, later in life. This was seen in the hypothalamus, striatum and limbic forebrain 91 , and frontal cortex 92 . In a study of CB 1 R agonist self-administration in rats 93 , THC exposure during adolescence enhanced the reinforcing effects of cannabinoids in adulthood, suggesting that exposure to THC during adolescence increased addiction potential during a critical period of development. Importantly, THC-exposed rodents had a reduced capacity for cannabinoid-induced increases in firing of dopaminergic neurons, consistent with a blunting of the dopamine response in adulthood.
Inconsistencies between animal and human studies
Preclinical evidence shows that acute THC administration increases nerve-firing rates and the results of animal studies using microdialysis indicate that acute THC challenge causes dopamine release, yet the results of experiments from human studies have not been consistent 94, 95 . A number of factors may underlie the inconsistencies in the results of the studies presented above.
The animal evidence indicates that differences in dopamine activity following THC administration are highly region-specific and include differing dopaminergic responses in the shell and core of the NAc 65 . Although human PET imaging provides a reliable measure of dopaminergic function in the striatum 59 , the spatial resolution of most PET cameras is approximately 4 mm, which limits accuracy when measuring activity in small brain volumes (such as in the core and shell of the NAc) owing to partial-volume and spill-over effects 96 . For the foreseeable future, therefore, human in vivo imaging techniques lack the spatial resolution to detect these complex effects on different parts of the dopamine pathway, whereas research on living human brain tissue in vitro of course raises substantial ethical challenges 97 . A further possibility underlying the lack of consistent dopamine release in the human studies is that the dose of THC used in human imaging studies has not been sufficient to consistently elicit measurable dopamine release. Human studies all involved the administration of 10 mg or less of THC because older pharmacological studies indicated that the 'standard joint' (or cannabis cigarette; defined by the US National Institute on Drug Abuse) delivered an approximate THC dose of 8-15 mg, equivalent to about 170 μg kg −1 (ref. 98) . These doses are considerably less than those used in animal microdialysis studies, which are typically around 1 mg kg −1
. Correspondingly, though, the THC content of cannabis has increased considerably since early clinical studies 99 , with current THC doses possibly exceeding 40 mg per joint 100 , meaning that the doses that were used in the published imaging studies no longer reflect typical THC exposure in cannabis users. The picture is further complicated by animal data indicating that THC exerts complex dose-dependent effects on the dopamine system 31 ; the dose-response profile for THC-induced dopamine release has not been investigated in humans so it is possible that human imaging studies are missing peak dopamine changes. Likewise, heterogeneity in animal data may be a reflection of time of sampling in Lower dopamine synthesis capacity in the dorsal striatum is directly associated with reduced motivation levels 102 , whereas reduced dopamine release in the ventral striatum is directly associated with negative emotion levels and severity of addiction 68 . Reduced dopamine release in the ventral striatum associated with negative emotionality and addiction severity.
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relation to THC treatment. For example, repeated daily THC administration led to an initial decrease in dopamine levels, followed by a gradual return to baseline in brains that were studied 1 h after THC dosing, but increases were subsequently observed 2 h after dosing 32 . This time period is consistent with acute release and diffusion away, followed by an upregulation of synthesis, increasing levels at 2 h. Other factors that may contribute to the complex temporal course of dopaminergic effects include intricate changes in dopamine synthesis and metabolism. These comprise both CB 1 R-mediated increases in tyrosine hydroxylase activity 36 and acute increases and longer-term decreases in monoamine oxidase activity 101 , indicating that THC may exert differential effects on the time courses of dopamine synthesis and degradation. Equally, the partial agonist properties of THC on the CB 1 R serve only to obfuscate its dopaminergic effects, since THC can both activate and block cannabinoid receptors in a region-specific and species-dependent manner, based on the density and efficiency of populations of receptors and the concentrations of endogenous agonists 19 .
There are a number of challenges involved in assessing the long-term effects of exposure to THC. First, it is plausible that discrepant findings may be attributable to the duration of THC treatment. Animal experiments are typically conducted following administration of THC for no longer than three weeks 63, 78, 84 , whereas human studies are conducted in participants who have taken cannabis over years (the duration of regular cannabis use is typically in excess of three years 102 ). Furthermore, it remains unclear to what degree homeostatic mechanisms are able to compensate for these alterations over time. Additionally, in humans there are a number of psychosocial and genetic risk factors that may predispose an individual to develop a cannabis use disorder. Given the evidence of interactions between early life psychological deprivation and THC-induced effects on dopamine in animals 74 , it is possible that the human data relating to cannabis-dependent participants is confounded by a range of environmental factors, including parental loss and other psychosocial factors 103 . Other environmental and physiological factors have been found to influence the dopaminergic effects of THC. Of particular relevance to humans is sleep deprivation, which decreases dopamine turnover in response to THC 104 , and stress, which increases THC-induced dopamine synthesis 105 . Cannabis also contains a multitude of other compounds, called phytocannabinoids, which probably exert different complex actions on the dopamine system. These compounds could be behind the varied response observed in human cannabis users when compared to the more consistent animal data that uses only THC. Owing to the co-morbidity of addictions, it is particularly challenging for human imaging researchers to recruit participants with cannabis dependence who do not use other psychoactive compounds, including nicotine and alcohol, in more naturalistic studies.
Finally, whether THC is delivered in a contingent or non-contingent way is likely to be important, given evidence that anticipation leads to dopamine release. In general, animal studies include a variety of contingencies around the dosing of THC. By contrast, in human acute studies THC was given to participants with a prior exposure to the drug but was not delivered in the habitual manner in which the drug is consumed, potentially reducing the degree of dopamine release.
Dopamine and the behavioural effects of THC
THC is associated with a number of behavioural effects that are likely to involve alterations in dopaminergic function. The first evidence of this came from early animal studies, which reported similarities between the behavioural effects of THC, including catalepsy and hypothermia 106 , and dopamine antagonists 107 . However, THC also antagonizes the locomotor and hyperthermic effects of amphetamine, which causes dopamine release 108 . These seemingly paradoxical effects may be due to the high doses used in the early research together with the partial agonist effects of THC and/or non-specific receptor-independent effects.
THC promotes increased food intake in animals 109 and humans 110 . Since appetite is modulated by the dopamine system 111 , studies have investigated dopaminergic involvement in THC-induced feeding. The dopamine D 1 receptor antagonist SCH23390 attenuated THC-induced feeding at a dose that did not affect feeding on its own 112 . Recent research has identified CB 1 R-mediated changes in hypothalamic proopiomelanocortin (POMC) neurons 113 as the potential underlying cause of this process, through mitochondrial uncoupling protein 2, which is involved in ghrelin-mediated dopaminergic function 114 . Heavy cannabis use is associated with impaired educational and occupational outcomes 115 . Factors that may underlie this association include cognitive impairment, which includes executive dysfunction 116 , working memory impairments 117 and amotivation 118 (defined as reduced motivation for goal-directed behaviour 119 ). These functions are susceptible to mesocortical dopaminergic manipulation 120 (for example, prefrontal D 1 receptor blockade 121 ). Although a preclinical study reported that D 2 receptor antagonism blocks THC-induced working memory deficits 122 , this was not replicated in humans 123 . Nonetheless, there is recent evidence that THC-induced workingmemory deficits are moderated by catechol-O-methyltransferase, a key enzyme in the dopamine metabolic pathway 124 , which also modulates the effects of THC use on dopaminergic cell size in adolescents 84 . Chronic heavy cannabis use produces apathetic behaviour in rhesus monkeys 125 , while a study in humans 102 found that the reduced dopamine synthesis capacity observed in heavy cannabis users was related to amotivation. Overlapping features of the amotivational syndrome associated with cannabis use disorders, such as reduced reward sensitivity and negative emotionality 126 , were also found to be inversely related to methylphenidate-induced dopamine ventral striatal dopamine release 68 . The dopamine system is involved in risk of psychosis 127 . An early case report described increased striatal dopamine release following cannabis intoxication, associated with the exacerbation of psychotic symptoms in a patient with schizophrenia 128 . Furthermore, cannabis users with a diagnosis of schizophrenia, and those at clinical high risk for schizophrenia, displayed blunted striatal stress-induced dopamine release 129 . Although dopamine release was blunted in cannabis users with schizophrenia, it was nevertheless directly related to the induction of psychotic symptoms 130 . Supersensivity of postsynaptic D 2 Rs 63 could explain this apparent paradox; alternatively it could be due to impaired endocannabinoid regulation of dopamine signal transduction. Patients with schizophrenia using high levels of cannabis show reduced anandamide levels, supporting the latter explanation 131 . Accordingly, cannabidiol, a phytocannabinoid compound that elevates anandamide levels, has been shown to reduce psychotic symptoms 132 . Alternative postsynaptic mechanisms include CB 1 R-D 2 R heterodimerization 133 and downstream intracellular mechanisms such as the neuregulin 1-erbB2 receptor tyrosine kinase 4-phosphoinositide 3 kinase-protein kinase B (NRG1-ERBB4-PI3K-AKT1) pathway 134 .
Outlook
There is now substantial evidence that THC exerts effects on the dopamine system in animals. The key challenges for the field must be to understand the complexity of these effects, identify how they translate to humans and appreciate how they relate to the potential negative effects of the drug in humans (Box 2). Animal studies demonstrate that the acute administration of THC causes region-specific increases in dopamine release and nerve activity-we must understand the functional significance of these increases. The available preclinical evidence suggests that chronic THC administration causes long-term changes to the dopamine system, but these models are limited as they do not reflect typical patterns of human use. Future studies should, therefore, be of longer duration to reflect human use and should also include co-administration with other drugs, such as nicotine and alcohol, which are commonly used with cannabis. Related to this is a need to understand how the dopaminergic effects of THC are modulated by the other phytocannabinoids. Human PET studies have demonstrated that dopamine synthesis and dopamine release are blunted in cannabis REVIEW RESEARCH users relative to non-users, yet we still need to understand the precise mechanisms through which this occurs.
It is necessary to identify whether the effects of THC on the dopamine system are reversible and, if they are not, to recognize when they become so. Likewise, further molecular imaging studies in humans are needed to determine the dose-response and timing of the acute effects of THC on dopamine release, and to determine whether there are regional differences in dopamine release-particularly between cortical and sub-cortical regions.
Ultimately, one key challenge in understanding the effects of THC on the dopamine system is translating results from animal studies, many of which cannot be carried out clinically, into humans. We must also reach consensus on THC dose equivalence across species. It is therefore difficult to know what the implications of some preclinical animal work are for human research and how to back-translate human findings into preclinical models. There must be movement away from untranslatable, standalone research, towards the use of translational techniques, such as PET and MRI approaches that can be conducted in both humans and preclinical models that can capture human use patterns in combination with traditional preclinical techniques. We must also understand how psychoactive metabolites of THC and endocannabinoids modulate THCinduced changes in dopaminergic function.
Given the changing patterns in cannabis use across the world, particularly in young people, and the increase in the THC content of cannabis, there is clearly a pressing need to understand how THC alters dopaminergic function. This is especially important given that emerging evidence that links dopaminergic alterations to a number of the adverse cognitive and behavioural consequences of THC, and that there is a dearth of current effective biological interventions for many of the psychiatric sequelae of cannabis use. Dopaminergic dysfunction may thus represent an area for future treatment targets.
There is evidence that gestational exposure to THC is associated with dysregulated dopamine synthesis in later life. This has major potential public health implications, given the prevalence of cannabis use in women of child-bearing age and that the liberalization of cannabis laws around the world may be associated with increased use of the drug amongst gravid and nursing mothers. However, there remain gaps in our knowledge of the developmental effects of THC. In particular, we do not know how long the dopaminergic effects persist for and what the behavioural consequences are. Perhaps most critically, we do not yet know what the effects of THC exposure are on the adolescent dopamine system. The available evidence indicates that THC exposure produces complex, diverse and potentially long-term effects on the dopamine system. These include increased nerve firing and dopamine release in response to acute THC, and dopaminergic blunting associated with long-term use. Future research should focus on probing the relationships between cannabis-induced alterations in the dopamine system and behavioural effects in humans and animal models.
BOX 2
Strategy for future work
Preclinical and clinical research • Identify the relationships between cannabis-induced alterations in the dopamine system and behavioural phenomena in humans and animal models • Use translational techniques that can be applied in human and animal studies alike and employ study designs that better reflect patterns of human use, including modelling contingency in acute THC challenge studies • Achieve consensus on dose equivalence across species • Determine whether THC-induced dopaminergic changes during key developmental phases persist into later life and whether this is linked to behavioural changes • Investigate how gene variants that modulate the endocannabinoid and dopamine systems influence the sensitivity to the rewarding effects of THC and vulnerability to addiction, amotivation and psychosis following chronic exposure • Investigate the effects of sex in THC response. This will be useful to understand the differences in susceptibility to cannabis effects that have been reported between males and females 72 . Preclinical research • Identify the effects on the dopamine system of long-term THC exposure alongside co-administration with nicotine to reflect typical patterns of human use • Determine the mechanisms underlying the complex dose-response effects of THC on dopaminergic function • Elucidate the mechanisms of regional differences in dopaminergic effects and the functional significance of these on behaviour • Determine if the long-term effects of THC are reversible with abstinence Clinical research • Determine if the blunted dopamine release and synthesis seen in chronic users is a pre-existing vulnerability factor or a direct result of repeated THC exposure • Determine the dopaminergic changes over the course of repeated THC exposures and dose-response effects • Achieve consensus on how to report previous exposure to cannabis use in the human literature • Determine whether there are regional differences in dopamine release in response to THC administration in humans • Determine the dose and context dependency of THC effects on the dopamine system
